Development and validation of a broadly cross-reactive polyclonal antibody as capture antibody for pan human β coronavirus antigen detection Authors: Qiang Wu, Zhan-Zhao Wang, Zhen-Ming Wang, Yu-Hui Wang Published: 2026 ABSTRACT Highlights•Antibodies were purified by antigen affinity chromatography conjugated with epitope peptides.•Prepared antibody could simultaneously recognize five β coronavirus nucleocapsid proteins.•Prepared antibody would be likely to recognize other newly emerging β coronavirus subspecies. Introduction To date, there are five human β-coronavirus (β-HCoVs) species, HCoV-OC43, HCoV-HKU1, SARS-CoV-1, MERS-CoV, and SARS-CoV-2, which could invade the human respiratory tract and cause pathological changes in tissues and organs. SARS-CoV-1, MERS-CoV, and SARS-CoV-2 have successively triggered three major coronavirus outbreaks in the 21st century leading to global public health crises, whereas HCoV-OC43 and HCoV-HKU1 typically cause mild upper respiratory tract infections (Cerato et al., 2023; Wu et al., 2020). The risk of cross-species transmission of β-coronavirus persists, as bats and other natural reservoirs may still harbor undiscovered β-coronaviruses (Toptun et al., 2025). Therefore, the development of rapid and broad-spectrum diagnostic methods capable of detecting β-coronavirus infections is essential for routine clinical testing and for early intervention in future emerging outbreaks. Virus antigen detection is one of several diagnostic approaches for viral infections. Compared with nucleic acid testing, antigen detection offers advantages such as operational simplicity, rapid turnaround time, and lower requirements for laboratory infrastructure and equipment, making it particularly suitable for point-of-care testing and resource-limited settings (Kimura et al., 2025). Furthermore, unlike virus antibody detection that reflects past infection, antigen detection directly indicates active infection status, providing real-time information on ongoing viral infection. Viral nucleocapsid (N) proteins, which characterized by high abundance in viral particles and high conservation across β-coronavirus species, have been chosen as the preferred targets for coronavirus antigen detection (Yamaoka et al., 2021; Sarkar et al., 2021). Coronavirus antigen detection reagents usually employ a double-antibody sandwich immunoassay format, using two highly specific antibodies that recognize distinct epitopes as capture and detection antibodies respectively. The design of such detection reagents prioritizes high specificity, requiring the selected antibodies to exhibit strict subtype specificity and no cross-reactivity with antigens from other coronavirus species. Numerous studies have developed double-antibody sandwich antigen detection systems based on N-protein-specific antibodies, effectively distinguishing different coronavirus subtypes with favorable sensitivity and specificity (Meyer et al., 2014; Cerutti et al., 2020; Lu et al., 2021; Hnasko et al., 2025). Mutua (Maurine et al., 2025) successfully expressed the SARS-CoV-2 N protein using a wheat germ cell-free protein expression system, and antibodies obtained from immunized BALB/c mice exhibited high reactivity with the N protein and no cross-reactivity with other respiratory viruses. Zhou (Zhou et al., 2023) prepared 90 monoclonal antibodies reactive exclusively with the SARS-CoV-2 N protein and identified the antigenic epitopes by synthesizing overlapping N protein peptides, showing no cross-reactivity with the N proteins of common human coronaviruses or MERS-CoV. N-protein antibodies have been widely used to construct double-antibody sandwich-based antigen detection system, achieving a sensitivity of over 90% and a specificity of over 95%, serving as a rapid screening tool for the control of respiratory virus transmission (Kim et al., 2021). It’s of note that pan-coronavirus cross-reactive antibodies, i.e., broad-spectrum reactive antibodies, have garnered considerable attention in the fields of vaccines and immunotherapy (Martinez et al., 2022; Zhou et al., 2023; Kim et al., 2024; Tan et al., 2021). Dacon (Dacon et al., 2023) identified 55 monoclonal antibodies from convalescent COVID-19 donors that bound to the spike proteins of multiple β-HCoVs. Among these antibodies, those targeting the S2 subunit of the spike protein exhibited broad neutralizing activity against β-HCoV from different lineages and demonstrated in vivo protective efficacy in a hamster model. In addition to the use in vaccines and therapeutic neutralizing antibodies, researchers have also begun to explore the potential of cross-reactive antibodies as diagnostic detection antibodies. Wen (Wen et al., 2023) isolated five N-specific monoclonal antibodies from memory B cells in the peripheral blood of two convalescent COVID-19 patients, which were cross-reactive to the N protein of SARS-CoV-1 but showed little to no cross-reactivity to the N proteins of other human beta coronaviruses. Liew (Liew et al., 2025) generated three broadly cross-reactive monoclonal antibodies by immunizing mice with recombinant N proteins of SARS-CoV-2 and MERS-CoV. One of these antibodies exhibited cross-reactivity against the subgenera Sarbecovirus, Merbecovirus and Hibecovirus, and successfully detected N protein in all clinical swab samples from COVID-19 patients by sandwich ELISA. These cross-reactive antibodies are primarily screened from virus-infected patients or N protein-immunized animals, as they efficiently recognize the complete spatial structure of target antigens and thus yield favorable antigen reactivity. The reported antibodies against the N proteins could cross-react with SARS-CoV-1, SARS-CoV-2 and MERS-CoV, but showed minimal cross-reactivity with N proteins of other human β coronaviruses such as OC43 and HKU1. The potential of broadly cross-reactive antibodies for human β-coronavirus antigen detection remains to be further explored. In the study, we aimed to develop broadly cross-reactive antibodies by immunizing New Zealand white rabbits with the conserved homologous peptides of β-HCoV nucleocapsid (N) proteins for use as universal capture antibodies in viral antigen detection. The broadly cross-reactive antibodies are capable of capturing five subtypes of β-HCoV within the genus, and when paired with another subtype-specific detection antibody in the sandwich format, they enable specific identification of individual β-HCoV subtypes. This strategy shows great potential as a flexible and versatile diagnostic platform for detecting diverse β-HCoV and tackling the risks posed by newly emerging pathogens in the future. Materials and methods Materials Nucleocapsid proteins of β-HCoVs and SARS-CoV-2 Nucleocapsid Antibody/HRP were purchased from SinoBiological (Beijing, China). PabPur SulfoLink Beads 4FF was purchased from Smart-Lifesciences (Changzhou, China). The NP peptide was synthesized by Shanghai Apeptide Co., Ltd (Shanghai, China). ELISA microplate was purchased from Corning Life Sciences (Conning, USA). Peristaltic Pump and UV Detector were obtained from HuXi Instrument Factory (Shanghai, China). Microplate Reader was purchased form HEALES Technology Development Co., Ltd. (Shenzhen, China). Goat Anti-Rabbit IgG/HRP, Goat Anti-Mouse IgG/HRP and TMB Single-Component Substrate Solution were purchased from Solarbio Life Sciences (Beijing, China). Sodium phosphate dibasic (Na2HPO4), sodium phosphate monobasic (NaH2PO4), ammonium sulphate ((NH4)2SO4) and sodium chloride (NaCl) were purchased from Sinopharm Chemical Reagent (Shanghai, China). All other chemicals were of analytical grade. Peptide design and synthesis The amino acid sequences of the nucleocapsid (N) protein of five β-HCoVs, namely SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-HKU1, and HCoV-OC43, were obtained from the NCBI database. Multiple sequence alignment of the N-protein amino acid sequences was subsequently performed using the Clustal Omega tool. The conserved homologous peptide region (NP) was selected as hapten, followed by cysteine (-Cys) modification at either the amino (-NH₂, N-terminus) or carboxyl (-COOH, C-terminus) terminus. The modified polypeptides were then chemically synthesized. For subsequent conjugation, the free sulfhydryl group (-SH) of cysteine residues was used to crosslink synthetic peptides with carrier proteins such as bovine serum albumin (BSA) or Keyhole Limpet Hemocyanin (KLH). Immunization of New Zealand white rabbits NP peptide–carrier protein conjugates were used as immunogens and emulsified with an equal volume (1:1, v/v) of complete or incomplete Freund’s adjuvant. New Zealand white rabbits were immunized with the appropriate dose of the emulsified immunogen, and the immunization protocol was shown in Table 1. One week after the second booster immunization, rabbit antisera were collected via marginal ear vein bleeding, and antiserum titers were determined by indirect enzyme-linked immunosorbent assay (ELISA). Antiserum titers were assessed to determine whether rabbits were eligible for final blood collection after three booster immunizations.Table 1Immunization protocol for New Zealand white rabbits.Table 1 dummy alt textImmunization NumberAdjuvant TypeInterval (Day)Immunization Dose (μg per rabbit)Immunization RoutePrimary immunizationFreund’s Complete Adjuvant—–250Multi-point subcutaneous injectionFirst booster immunizationFreund’s Incomplete Adjuvant21250Multi-point subcutaneous injectionSecond booster immunizationFreund’s Incomplete Adjuvant14250Multi-point subcutaneous injectionThird booster immunizationFreund’s Incomplete Adjuvant14250Multi-point subcutaneous injectionNote: Two female rabbits at 12 weeks of age (weight ≈ 2.3 kg) were chosen to be immunized. Table 1Immunization protocol for New Zealand white rabbits.Table 1 dummy alt textImmunization NumberAdjuvant TypeInterval (Day)Immunization Dose (μg per rabbit)Immunization RoutePrimary immunizationFreund’s Complete Adjuvant—–250Multi-point subcutaneous injectionFirst booster immunizationFreund’s Incomplete Adjuvant21250Multi-point subcutaneous injectionSecond booster immunizationFreund’s Incomplete Adjuvant14250Multi-point subcutaneous injectionThird booster immunizationFreund’s Incomplete Adjuvant14250Multi-point subcutaneous injectionNote: Two female rabbits at 12 weeks of age (weight ≈ 2.3 kg) were chosen to be immunized. Immunization protocol for New Zealand white rabbits. Note: Two female rabbits at 12 weeks of age (weight ≈ 2.3 kg) were chosen to be immunized. Evaluation of rabbit immune efficacy by indirect ELISA The titers of antisera from rabbits immunized with the NP peptides were determined using indirect ELISA. The microplates were coated with full-length N protein at a concentration of 2.0 μg/mL and incubated overnight at 2–8 °C. After washing with PBST (20 mM PBS, pH 7.4, 0.05% Tween-20), the plates were blocked with 5% skimmed milk at 37 °C for 2 h. Following another PBST wash, rabbit antiserum was initially diluted 1:500 in the first well, followed by two-fold serial column dilution across the microplate, and incubated at 37 °C for 1 h. After PBST washing, goat anti-rabbit secondary antibody conjugated with horseradish peroxidase (HRP) diluted at 1:2000 was added, and the plates were incubated at 37 °C for another 1 h. The reaction was developed with tetramethylbenzidine (TMB) substrate and terminated by the addition of 2 M H₂SO₄. The absorbance at 450 nm was measured using a microplate reader. Preparation of antigen affinity chromatographic media The NP peptides were conjugated with PabPur SulfoLink Beads 4FF to prepare the antigen affinity media for the antibody purification. PabPur SulfoLink Beads were transferred into a gravity chromatography column, and the storage solution was drained by gravity flow. The resin was equilibrated and washed with 9 column volumes of coupling buffer (50 mM Tris, 5 mM EDTA-Na, pH 8.5). The thiol-containing NP peptides dissolved in the coupling buffer were added to the column followed by incubation with gentle agitation at 28 °C for 30 min. After the solution was completely drained, an equal volume of blocking buffer (50 mM Tris, 5 mM EDTA-Na, 50 mM L-cysteine, pH 8.5) was added to block unreacted free thiol groups with incubation at 28 °C for 30 min. The blocking buffer was then removed and the resin was washed with 3 column volumes of deionized water. Finally, the affinity resin was resuspended in the storage buffer (1 × PBS containing 20% ethanol) and stored at 2∼8 °C. Antibody purification (1)Preliminary purification of antibodies via ammonium sulfate precipitationSolid (NH4)2 SO4 powder was slowly added into rabbit antiserum to achieve 50% (NH4)2 SO4 saturation under constant stirring. The mixture was stirred for at least 1 h and then centrifuged at 6800 rpm for 45 min. The supernatant was discarded, and the precipitate was redissolved in PBS (0.01 M, pH 7.4). The above procedure was repeated once and the redissolved precipitate was dialyzed in PBS buffer with the dialysate changed 3∼5 times.(2)Further purification of antibodies by antigen affinity chromatographyAntigen affinity chromatographic resin coupled with NP peptides could specifically purify antibodies whose antigenic epitopes were NP peptides. The affinity resin packed into a chromatographic column was first rinsed with 3∼5 column volumes of deionized water and then equilibrated with PBS buffer (0.01 M, pH 7.4). The preliminarily purified antibody sample was loaded onto the affinity column using a peristaltic pump. After sample loading was completed, the affinity column was washed with PBS buffer. Protein elution was performed using glycine buffer (0.1 M, pH 3.0). The eluted fractions were collected separately, which were neutralized with 1/10 volume of neutralizing buffer (1 M Tris–HCl, pH 8.5). The purity of the purified antibody (NPA) was analyzed by SDS-PAGE and the reactivity of the antibody was determined by ELISA. (1)Preliminary purification of antibodies via ammonium sulfate precipitationSolid (NH4)2 SO4 powder was slowly added into rabbit antiserum to achieve 50% (NH4)2 SO4 saturation under constant stirring. The mixture was stirred for at least 1 h and then centrifuged at 6800 rpm for 45 min. The supernatant was discarded, and the precipitate was redissolved in PBS (0.01 M, pH 7.4). The above procedure was repeated once and the redissolved precipitate was dialyzed in PBS buffer with the dialysate changed 3∼5 times. Preliminary purification of antibodies via ammonium sulfate precipitation Solid (NH4)2 SO4 powder was slowly added into rabbit antiserum to achieve 50% (NH4)2 SO4 saturation under constant stirring. The mixture was stirred for at least 1 h and then centrifuged at 6800 rpm for 45 min. The supernatant was discarded, and the precipitate was redissolved in PBS (0.01 M, pH 7.4). The above procedure was repeated once and the redissolved precipitate was dialyzed in PBS buffer with the dialysate changed 3∼5 times. (2)Further purification of antibodies by antigen affinity chromatographyAntigen affinity chromatographic resin coupled with NP peptides could specifically purify antibodies whose antigenic epitopes were NP peptides. The affinity resin packed into a chromatographic column was first rinsed with 3∼5 column volumes of deionized water and then equilibrated with PBS buffer (0.01 M, pH 7.4). The preliminarily purified antibody sample was loaded onto the affinity column using a peristaltic pump. After sample loading was completed, the affinity column was washed with PBS buffer. Protein elution was performed using glycine buffer (0.1 M, pH 3.0). The eluted fractions were collected separately, which were neutralized with 1/10 volume of neutralizing buffer (1 M Tris–HCl, pH 8.5). The purity of the purified antibody (NPA) was analyzed by SDS-PAGE and the reactivity of the antibody was determined by ELISA. Further purification of antibodies by antigen affinity chromatography Antigen affinity chromatographic resin coupled with NP peptides could specifically purify antibodies whose antigenic epitopes were NP peptides. The affinity resin packed into a chromatographic column was first rinsed with 3∼5 column volumes of deionized water and then equilibrated with PBS buffer (0.01 M, pH 7.4). The preliminarily purified antibody sample was loaded onto the affinity column using a peristaltic pump. After sample loading was completed, the affinity column was washed with PBS buffer. Protein elution was performed using glycine buffer (0.1 M, pH 3.0). The eluted fractions were collected separately, which were neutralized with 1/10 volume of neutralizing buffer (1 M Tris–HCl, pH 8.5). The purity of the purified antibody (NPA) was analyzed by SDS-PAGE and the reactivity of the antibody was determined by ELISA. Performance validation of the purified polyclonal antibodies (1)Reactivity of NPA antibodies with N proteins verified by Iindirect ELISAThe full-length N proteins of five β-HCoV, namely SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-HKU1 and HCoV-OC43 were coated in microplates. The reactivity of the NPA antibody against β-HCoV N antigens was verified by indirect ELISA. Detailed procedures were performed as described in Section 2.4.(2)Competitive ELISA for evaluating the capturing performance of NPA antibody against N antigens of MERS-CoV, HKU1-CoV, and OC43-CoV.The competitive ELISA was employed to assess the capturing ability of the NPA antibody toward the three N antigens. The NPA antibody was used as the capture antibody and coated onto ELISA plates at 5 μg/mL. The plates were incubated with the respective N proteins of MERS-CoV, HKU1-CoV, and OC43-CoV with the concentration of 20 μg/mL at 37 °C for 2 h. After washing, two concentrations 5 μg/mL and 2.5 μg/mL of SARS-CoV-1 N proteins were added to the wells corresponding to two experimental groups, followed by the addition of the HRP-conjugated antibody specific for SARS-CoV-1 N protein as the detection antibody. Finally, OD450 values were statistically analyzed to assess whether pre-incubated N proteins of MERS-CoV, HCoV-HKU1 and HCoV-OC43 could compete with SARS-CoV-1 N protein for NPA antibody binding.(3)Capture capability of NPA antibodies against N proteins of SARS CoV-2 and SARS CoV-1 verified by sandwich ELISAThe SARS CoV-2 and SARS CoV-1 nucleocapsid N protein, as the representative of β-HCoV antigens, were used to validate the antigen-capturing ability of NPA antibodies by sandwich ELISA. Firstly, NPA antibody at 2 μg/mL was coated in microplates and incubated overnight at 2–8 °C. After washing with PBST, the plates were blocked with 5% skimmed milk at 37 °C for 2 h. Following PBST washing, N proteins of the SARS CoV-2 at an initial concentration of 200 ng/mL were applied and serially two-fold diluted across different concentration gradients, then incubated at 37 °C for 1 h. After another PBST wash, the anti-N-protein antibody conjugated horseradish peroxidase (HRP) diluted at 1:2000 was added followed by incubation at 37 °C for 1 h. The color reaction was developed with TMB as the substrate to react with HRP at room temperature for 10 min and terminated by adding 2 M H₂SO₄. The absorbance at 450 nm was measured using a microplate reader, which was used to evaluate the capture performance of NPA antibody against N protein antigen. (1)Reactivity of NPA antibodies with N proteins verified by Iindirect ELISAThe full-length N proteins of five β-HCoV, namely SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-HKU1 and HCoV-OC43 were coated in microplates. The reactivity of the NPA antibody against β-HCoV N antigens was verified by indirect ELISA. Detailed procedures were performed as described in Section 2.4. Reactivity of NPA antibodies with N proteins verified by Iindirect ELISA The full-length N proteins of five β-HCoV, namely SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-HKU1 and HCoV-OC43 were coated in microplates. The reactivity of the NPA antibody against β-HCoV N antigens was verified by indirect ELISA. Detailed procedures were performed as described in Section 2.4. (2)Competitive ELISA for evaluating the capturing performance of NPA antibody against N antigens of MERS-CoV, HKU1-CoV, and OC43-CoV.The competitive ELISA was employed to assess the capturing ability of the NPA antibody toward the three N antigens. The NPA antibody was used as the capture antibody and coated onto ELISA plates at 5 μg/mL. The plates were incubated with the respective N proteins of MERS-CoV, HKU1-CoV, and OC43-CoV with the concentration of 20 μg/mL at 37 °C for 2 h. After washing, two concentrations 5 μg/mL and 2.5 μg/mL of SARS-CoV-1 N proteins were added to the wells corresponding to two experimental groups, followed by the addition of the HRP-conjugated antibody specific for SARS-CoV-1 N protein as the detection antibody. Finally, OD450 values were statistically analyzed to assess whether pre-incubated N proteins of MERS-CoV, HCoV-HKU1 and HCoV-OC43 could compete with SARS-CoV-1 N protein for NPA antibody binding. Competitive ELISA for evaluating the capturing performance of NPA antibody against N antigens of MERS-CoV, HKU1-CoV, and OC43-CoV. The competitive ELISA was employed to assess the capturing ability of the NPA antibody toward the three N antigens. The NPA antibody was used as the capture antibody and coated onto ELISA plates at 5 μg/mL. The plates were incubated with the respective N proteins of MERS-CoV, HKU1-CoV, and OC43-CoV with the concentration of 20 μg/mL at 37 °C for 2 h. After washing, two concentrations 5 μg/mL and 2.5 μg/mL of SARS-CoV-1 N proteins were added to the wells corresponding to two experimental groups, followed by the addition of the HRP-conjugated antibody specific for SARS-CoV-1 N protein as the detection antibody. Finally, OD450 values were statistically analyzed to assess whether pre-incubated N proteins of MERS-CoV, HCoV-HKU1 and HCoV-OC43 could compete with SARS-CoV-1 N protein for NPA antibody binding. (3)Capture capability of NPA antibodies against N proteins of SARS CoV-2 and SARS CoV-1 verified by sandwich ELISAThe SARS CoV-2 and SARS CoV-1 nucleocapsid N protein, as the representative of β-HCoV antigens, were used to validate the antigen-capturing ability of NPA antibodies by sandwich ELISA. Firstly, NPA antibody at 2 μg/mL was coated in microplates and incubated overnight at 2–8 °C. After washing with PBST, the plates were blocked with 5% skimmed milk at 37 °C for 2 h. Following PBST washing, N proteins of the SARS CoV-2 at an initial concentration of 200 ng/mL were applied and serially two-fold diluted across different concentration gradients, then incubated at 37 °C for 1 h. After another PBST wash, the anti-N-protein antibody conjugated horseradish peroxidase (HRP) diluted at 1:2000 was added followed by incubation at 37 °C for 1 h. The color reaction was developed with TMB as the substrate to react with HRP at room temperature for 10 min and terminated by adding 2 M H₂SO₄. The absorbance at 450 nm was measured using a microplate reader, which was used to evaluate the capture performance of NPA antibody against N protein antigen. Capture capability of NPA antibodies against N proteins of SARS CoV-2 and SARS CoV-1 verified by sandwich ELISA The SARS CoV-2 and SARS CoV-1 nucleocapsid N protein, as the representative of β-HCoV antigens, were used to validate the antigen-capturing ability of NPA antibodies by sandwich ELISA. Firstly, NPA antibody at 2 μg/mL was coated in microplates and incubated overnight at 2–8 °C. After washing with PBST, the plates were blocked with 5% skimmed milk at 37 °C for 2 h. Following PBST washing, N proteins of the SARS CoV-2 at an initial concentration of 200 ng/mL were applied and serially two-fold diluted across different concentration gradients, then incubated at 37 °C for 1 h. After another PBST wash, the anti-N-protein antibody conjugated horseradish peroxidase (HRP) diluted at 1:2000 was added followed by incubation at 37 °C for 1 h. The color reaction was developed with TMB as the substrate to react with HRP at room temperature for 10 min and terminated by adding 2 M H₂SO₄. The absorbance at 450 nm was measured using a microplate reader, which was used to evaluate the capture performance of NPA antibody against N protein antigen. Meanwhile, throat swab specimens from SARS-CoV-2-infected individuals were selected as real clinical samples. Using the same protocol described above, sandwich ELISA was performed to verify the capture ability of the prepared NPA antibody for N protein in authentic clinical specimens. The cut-off value was determined as the mean of OD450 value of negative samples plus three standard deviations (mean + 3 × SD). Results Design and synthesis of polypeptide as immunogen Homologous peptide fragment of nucleocapsid (N) protein from five β-HCoVs, namely SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-HKU1, and HCoV-OC43, was selected as haptens. Amino acid sequences of the N proteins from the five β- coronaviruses were aligned using the Clustal Omega tool (Fig. 1a). Sequence comparison revealed that the N protein of SARS-CoV-2 shared 90% and 48.5% amino acid homology with those of SARS-CoV-1 and MERS-CoV, respectively, whereas the N protein shared only 38.9% and 36.8% homology with HCoV-HKU1 and HCoV-OC43, respectively. Notably, a highly conserved peptide sequence PRWYFYYLGTGP (designated NP) was identified at approximately amino acid positions 75–110 near the N-terminus among the five N proteins. Three-dimensional structural analysis using PyMOL revealed that the NP segment is located on the surface of the viral N protein (Fig. 1b). Furthermore, the B cell linear epitope of NP segments was predicted using the BepiPred-3.0 tool with the predicted score of 0.239 (the threshold = 0.151), indicating that it is a potential antigenic epitope. Collectively, the NP peptide was identified as an optimal candidate epitope with favorable surface accessibility, rational structural localization and reliable predicted antigenicity.Fig. 1aAlignment of partial amino acid sequences of nucleocapsid N proteins from five human β coronaviruses. (The conserved homologous peptide sequences were indicated by shading).Fig 1a dummy alt textFig. 1bThree-dimensional structure diagram of the N protein-NH2 terminal region of the human β-coronavirus nucleocapsid.Fig 1b dummy alt text Alignment of partial amino acid sequences of nucleocapsid N proteins from five human β coronaviruses. (The conserved homologous peptide sequences were indicated by shading). Three-dimensional structure diagram of the N protein-NH2 terminal region of the human β-coronavirus nucleocapsid. The NP peptide was synthesized with cysteine (-Cys) modification at the C- terminus, which provides a free sulfhydryl group (-SH) for conjugation to carrier proteins. As shown in Fig. 2, mass spectrometry (MS) and high-performance liquid chromatography (HPLC) characterization confirmed that the synthetic peptide exhibited satisfactory molecular weight integrity and purity. The synthetic peptide was subsequently conjugated to the carrier protein (bovine serum albumin, BSA) using Succinimidyl 4-[N-maleimidomethyl] cyclohexane-1-carboxylate (SMCC). As illustrated in Fig. 3, the molecular weight of the peptide–BSA conjugate was markedly higher than that of native BSA, indicating efficient conjugation between the NP peptide and BSA. The conjugate could be used as an immunogen for subsequent animal immunization.Fig. 2Identification of the synthetic peptide molecular weight and purity by MS and HPLC respectively.Fig 2 dummy alt textFig. 3SDS-PAGE identification of peptide-BSA conjugation.Fig 3 dummy alt text Identification of the synthetic peptide molecular weight and purity by MS and HPLC respectively. SDS-PAGE identification of peptide-BSA conjugation. Immunization of New Zealand white rabbits The NP peptide-BSA conjugate, serving as the immunogen, was emulsified with Freund’s incomplete/complete adjuvant at a 1:1 (v/v) ratio. New Zealand white rabbits were immunized according to the established protocol. One week after the second booster immunization, rabbit antisera were collected via marginal ear vein bleeding. The antisera were diluted 1:500 followed by two-fold serial dilution, and their titers were determined by indirect ELISA coated with recombinant SARS-CoV-2 N protein. As shown in Fig. 4, the titers of post-immunization rabbit antisera could reach 1:8000, which were significantly increased compared with that obtained from pre-immunization sera, indicating a favorable immune response. The results verified the validity of the designed NP peptide and confirmed that rabbit immunization with this peptide successfully induced antibodies that recognize the full-length nucleocapsid (N) protein of SARS-CoV-2.Fig. 4Detection of anti-serum titer of immunized rabbits against N protein (The coating antigen of ELISA was the full-length N protein of SARS-CoV-2; a total of 2 rabbits were immunized; the blank control was the serum from pre-immunized rabbits).Fig 4 dummy alt text Detection of anti-serum titer of immunized rabbits against N protein (The coating antigen of ELISA was the full-length N protein of SARS-CoV-2; a total of 2 rabbits were immunized; the blank control was the serum from pre-immunized rabbits). Antibody purification from antiserum Preliminary antibody purification from rabbit antiserum was performed using the ammonium sulfate precipitation method. Further purification was performed via antigen affinity chromatography using NP peptide-conjugated resin. Antibodies targeting the NP peptide antigenic epitopes were adsorbed onto the affinity column and eluted with glycine buffer (pH 3.0), while other non-specific antibodies flowed through the column directly as shown in Fig. 5. The purity of the purified antibodies (NPA) exceeded 90% by SDS-PAGE analysis shown in Fig. 6. High purity could ensure antibody storage stability and reaction uniformity.Fig. 5The antibody purification by affinity chromatography column.Fig 5 dummy alt textFig. 6SDS-PAGE for antibody purification (L1:Protein marker, with molecular weights from top to bottom: 180, 130, 95, 72, 55, 43, 33, 25, 17 kDa; L2: Antibodies preliminarily purified by ammonium sulfate precipitation method; L3: The breakthrough of antibody purification by the affinity chromatography. L4: Elution 1 of antibodies purified by affinity chromatography; L5: Elution 2 of antibodies purified by affinity chromatography.).Fig 6 dummy alt text The antibody purification by affinity chromatography column. SDS-PAGE for antibody purification (L1:Protein marker, with molecular weights from top to bottom: 180, 130, 95, 72, 55, 43, 33, 25, 17 kDa; L2: Antibodies preliminarily purified by ammonium sulfate precipitation method; L3: The breakthrough of antibody purification by the affinity chromatography. L4: Elution 1 of antibodies purified by affinity chromatography; L5: Elution 2 of antibodies purified by affinity chromatography.). Validation of the reaction performance of the purified antibody (1)Validation of reactivity between NPA antibody and N antigens by indirect ELISAN proteins of SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-HKU1 and HCoV-OC43 were coated onto microtiter plates at a concentration of 2 μg/mL, while respiratory syncytial virus (RSV) N protein was selected as the negative control. The reactivity of the NPA antibody against N antigens of the five β-HCoVs was verified using an indirect ELISA. Each viral antigen was coated in an individual column of the plate. The first well was loaded with 2 μg/mL NPA antibody, which was then subjected to two-fold serial dilutions across the plate. As shown in Fig. 7, the NPA antibody could react with the N antigens of the five β-HCoVs, while no significant reactivity was observed in the negative control group with RSV N protein. The NPA antibody exhibited distinct binding intensities toward N proteins of different β-HCoV subtypes. This discrepancy may result from inconsistencies between the nominal concentrations of commercial N antigens and their actual effective concentrations. Although the antigen concentrations used for coating ELISA plates were uniformly 2 μg/mL, deviations may exist in the actual effective concentrations of coated antigens. In addition, although the NPA antibody targeted the conserved homologous sequences of the N proteins from the five β-coronaviruses, variations in the spatial conformation of individual viral N proteins altered the epitope recognition efficiency of the NPA antibody. Nevertheless, the results showed that the NPA antibody could recognize the N proteins of the five β-HCoVs.Fig. 7Verification of the reactivity of NPA antibody with five β-coronaviruse N proteins by indirect ELISA.Fig 7 dummy alt text(2)Validation of the capture performance of NPA antibodies against N proteins of SARS-CoV-2 and SARS-CoV-1 by sandwich ELISAThe N proteins of SARS-CoV-2 and SARS-CoV-1 were used as target antigens to evaluate the capture performance of NPA antibody via sandwich ELISA. Microplates were pre-coated with 10 μg/mL NPA antibody, followed by the addition of N proteins (2 μg/mL), which were subsequently two-fold serially diluted. Subsequently, commercial HRP-labeled antibodies targeting SARS-CoV-2 and SARS-CoV-1 N proteins diluted at 1:2000 was added to form the "sandwich" reaction format. The resulting color reaction demonstrated the capture capacity of the NPA antibody for different concentrations of the N protein. As shown in Table 2, the reactivity trend between the NPA antibody and varying concentrations of the N protein exhibited a typical linear dose–response trend, indicating that the NPA antibody possessed favorable capture ability for the N protein.Table 2Reaction of NPA antibody against SARS-CoV-2 and SARS-CoV-1 as the capture targets by sandwich ELISA.Table 2 dummy alt textConcentration of N proteins (ng/ml)2000100050025012562.531.25ODValueSARS-Cov-2 N0.446±0.0340.188±0.0370.091±0.0140.054±0.0100.037±0.0030.022±0.0020.017±0.003SARS-Cov-1 N0.788±0.0480.313±0.0170.145±0.0050.070±0.0020.043±0.0010.026±0.0040.018±0.007ReactionImageSARS-Cov-2 NImage, table 2 dummy alt textSARS-Cov-1 NNote: The OD values corresponded one-to-one with the pores in the color reaction image (from left to right) with different concentration of N proteins. The OD values represented the mean of twice independent replicate experiments.(3)Validation of the capture performance of the NPA antibody for MERS-CoV, HKU1-CoV and OC43-CoV N antigens by competitive ELISAThe competitive ELISA was established to evaluate the capture capability of the NPA antibody against the N proteins of MERS-CoV, HKU1-CoV and OC43-CoV. The NPA antibody was coated onto ELISA plates as the capture antibody followed by incubation with MERS-CoV, HKU1-CoV or OC43-CoV N antigens separately. Then, SARS-CoV-1 N protein was added followed by incubation with the HRP-conjugated anti-SARS-CoV-1 N protein antibody as the detection antibody. As shown in Fig. 8, the OD values of the experimental groups that included competitive MERS-CoV, HKU1-CoV or OC43-CoV N antigens were all reduced compared with the control group (without competing antigen). Statistical analysis using the t-test revealed p-values <0.05, indicating a significant difference compared to blank control. The results demonstrated that the three N proteins effectively competed with SARS-CoV-1 N protein for binding to the NPA antibody, thereby confirming that the NPA antibody could capture the N proteins of MERS-CoV, HKU1-CoV and OC43-CoV.Fig. 8Validation of the capture performance of the NPA antibody for MERS-CoV, HKU1-CoV and OC43-CoV N antigens by competitive ELISA. (The blank control represents wells without competitive N proteins of MERS-CoV, HKU1-CoV and OC43-CoV, processed identically. *** p < 0.05 represents significant difference compared to blank control. Data for each group represented the mean of three independent replicate experiments.).Fig 8 dummy alt text(4)The reactivity of NPA antibodies in detecting real clinical samplesThroat swab specimens collected from SARS-CoV-2 infected patients were selected to represent a real-world clinical application setting. Following the same protocol, the sandwich ELISA was conducted to validate the capture performance of the NPA antibody for the N protein in authentic clinical specimens. As shown in Table 3, the cut-off value was determined to be 0.0308, which was calculated as the mean value of OD450 nm derived from negative sample wells plus three times their standard deviation, and 6 of 8 nucleic acid-positive specimens yielded positive detection results. The results collectively demonstrated that the NPA antibody prepared in the study could be used as the capture antibody in β-coronavirus antigen detection.Table 3Reaction of NPA antibody against clinical specimens as the capture antibody by sandwich ELISA.Table 3 dummy alt textclinical specimenss1s2s3s4s5s6s7s8Nucleic acid TestPositive(Ct=37.5)Positive(Ct=32.0)Positive(Ct=19.1)Positive(Ct=22.0)Positive(Ct=15.8)Positive(Ct=19.7)negativenegativeODValue0.01970.02890.15280.17180.26760.19130.01770.0179ReactionImageImage, table 3 dummy alt textclinical specimensS9S10S11S12S13S14BlankControlPositiveControlNucleic acid TestnegativenegativenegativePositive(Ct=23.0)Positive(Ct=27.0)negative————ODValue0.01900.02060.02710.13150.12910.01880.01120.9654ReactionImageImage, table 3 dummy alt textNote: The OD values corresponded one-to-one with the wells in the color reaction image with different clinical specimens (s1∼s8). The clinical specimens were detected using SARS-CoV-2 Nucleic Acid Detection Kit (Fluorescence RT-PCR) from BioPerfectus Technologies Co., Ltd. The blank control and positive control were prepared by replacing clinical specimens with 1% BSA and 5 μg/mL N protein of SARS-CoV-2, respectively. (1)Validation of reactivity between NPA antibody and N antigens by indirect ELISAN proteins of SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-HKU1 and HCoV-OC43 were coated onto microtiter plates at a concentration of 2 μg/mL, while respiratory syncytial virus (RSV) N protein was selected as the negative control. The reactivity of the NPA antibody against N antigens of the five β-HCoVs was verified using an indirect ELISA. Each viral antigen was coated in an individual column of the plate. The first well was loaded with 2 μg/mL NPA antibody, which was then subjected to two-fold serial dilutions across the plate. As shown in Fig. 7, the NPA antibody could react with the N antigens of the five β-HCoVs, while no significant reactivity was observed in the negative control group with RSV N protein. The NPA antibody exhibited distinct binding intensities toward N proteins of different β-HCoV subtypes. This discrepancy may result from inconsistencies between the nominal concentrations of commercial N antigens and their actual effective concentrations. Although the antigen concentrations used for coating ELISA plates were uniformly 2 μg/mL, deviations may exist in the actual effective concentrations of coated antigens. In addition, although the NPA antibody targeted the conserved homologous sequences of the N proteins from the five β-coronaviruses, variations in the spatial conformation of individual viral N proteins altered the epitope recognition efficiency of the NPA antibody. Nevertheless, the results showed that the NPA antibody could recognize the N proteins of the five β-HCoVs.Fig. 7Verification of the reactivity of NPA antibody with five β-coronaviruse N proteins by indirect ELISA.Fig 7 dummy alt text Validation of reactivity between NPA antibody and N antigens by indirect ELISA N proteins of SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-HKU1 and HCoV-OC43 were coated onto microtiter plates at a concentration of 2 μg/mL, while respiratory syncytial virus (RSV) N protein was selected as the negative control. The reactivity of the NPA antibody against N antigens of the five β-HCoVs was verified using an indirect ELISA. Each viral antigen was coated in an individual column of the plate. The first well was loaded with 2 μg/mL NPA antibody, which was then subjected to two-fold serial dilutions across the plate. As shown in Fig. 7, the NPA antibody could react with the N antigens of the five β-HCoVs, while no significant reactivity was observed in the negative control group with RSV N protein. The NPA antibody exhibited distinct binding intensities toward N proteins of different β-HCoV subtypes. This discrepancy may result from inconsistencies between the nominal concentrations of commercial N antigens and their actual effective concentrations. Although the antigen concentrations used for coating ELISA plates were uniformly 2 μg/mL, deviations may exist in the actual effective concentrations of coated antigens. In addition, although the NPA antibody targeted the conserved homologous sequences of the N proteins from the five β-coronaviruses, variations in the spatial conformation of individual viral N proteins altered the epitope recognition efficiency of the NPA antibody. Nevertheless, the results showed that the NPA antibody could recognize the N proteins of the five β-HCoVs.Fig. 7Verification of the reactivity of NPA antibody with five β-coronaviruse N proteins by indirect ELISA.Fig 7 dummy alt text Verification of the reactivity of NPA antibody with five β-coronaviruse N proteins by indirect ELISA. (2)Validation of the capture performance of NPA antibodies against N proteins of SARS-CoV-2 and SARS-CoV-1 by sandwich ELISAThe N proteins of SARS-CoV-2 and SARS-CoV-1 were used as target antigens to evaluate the capture performance of NPA antibody via sandwich ELISA. Microplates were pre-coated with 10 μg/mL NPA antibody, followed by the addition of N proteins (2 μg/mL), which were subsequently two-fold serially diluted. Subsequently, commercial HRP-labeled antibodies targeting SARS-CoV-2 and SARS-CoV-1 N proteins diluted at 1:2000 was added to form the "sandwich" reaction format. The resulting color reaction demonstrated the capture capacity of the NPA antibody for different concentrations of the N protein. As shown in Table 2, the reactivity trend between the NPA antibody and varying concentrations of the N protein exhibited a typical linear dose–response trend, indicating that the NPA antibody possessed favorable capture ability for the N protein.Table 2Reaction of NPA antibody against SARS-CoV-2 and SARS-CoV-1 as the capture targets by sandwich ELISA.Table 2 dummy alt textConcentration of N proteins (ng/ml)2000100050025012562.531.25ODValueSARS-Cov-2 N0.446±0.0340.188±0.0370.091±0.0140.054±0.0100.037±0.0030.022±0.0020.017±0.003SARS-Cov-1 N0.788±0.0480.313±0.0170.145±0.0050.070±0.0020.043±0.0010.026±0.0040.018±0.007ReactionImageSARS-Cov-2 NImage, table 2 dummy alt textSARS-Cov-1 NNote: The OD values corresponded one-to-one with the pores in the color reaction image (from left to right) with different concentration of N proteins. The OD values represented the mean of twice independent replicate experiments. Validation of the capture performance of NPA antibodies against N proteins of SARS-CoV-2 and SARS-CoV-1 by sandwich ELISA The N proteins of SARS-CoV-2 and SARS-CoV-1 were used as target antigens to evaluate the capture performance of NPA antibody via sandwich ELISA. Microplates were pre-coated with 10 μg/mL NPA antibody, followed by the addition of N proteins (2 μg/mL), which were subsequently two-fold serially diluted. Subsequently, commercial HRP-labeled antibodies targeting SARS-CoV-2 and SARS-CoV-1 N proteins diluted at 1:2000 was added to form the "sandwich" reaction format. The resulting color reaction demonstrated the capture capacity of the NPA antibody for different concentrations of the N protein. As shown in Table 2, the reactivity trend between the NPA antibody and varying concentrations of the N protein exhibited a typical linear dose–response trend, indicating that the NPA antibody possessed favorable capture ability for the N protein.Table 2Reaction of NPA antibody against SARS-CoV-2 and SARS-CoV-1 as the capture targets by sandwich ELISA.Table 2 dummy alt textConcentration of N proteins (ng/ml)2000100050025012562.531.25ODValueSARS-Cov-2 N0.446±0.0340.188±0.0370.091±0.0140.054±0.0100.037±0.0030.022±0.0020.017±0.003SARS-Cov-1 N0.788±0.0480.313±0.0170.145±0.0050.070±0.0020.043±0.0010.026±0.0040.018±0.007ReactionImageSARS-Cov-2 NImage, table 2 dummy alt textSARS-Cov-1 NNote: The OD values corresponded one-to-one with the pores in the color reaction image (from left to right) with different concentration of N proteins. The OD values represented the mean of twice independent replicate experiments. Table 2Reaction of NPA antibody against SARS-CoV-2 and SARS-CoV-1 as the capture targets by sandwich ELISA.Table 2 dummy alt textConcentration of N proteins (ng/ml)2000100050025012562.531.25ODValueSARS-Cov-2 N0.446±0.0340.188±0.0370.091±0.0140.054±0.0100.037±0.0030.022±0.0020.017±0.003SARS-Cov-1 N0.788±0.0480.313±0.0170.145±0.0050.070±0.0020.043±0.0010.026±0.0040.018±0.007ReactionImageSARS-Cov-2 NImage, table 2 dummy alt textSARS-Cov-1 NNote: The OD values corresponded one-to-one with the pores in the color reaction image (from left to right) with different concentration of N proteins. The OD values represented the mean of twice independent replicate experiments. Reaction of NPA antibody against SARS-CoV-2 and SARS-CoV-1 as the capture targets by sandwich ELISA. Note: The OD values corresponded one-to-one with the pores in the color reaction image (from left to right) with different concentration of N proteins. The OD values represented the mean of twice independent replicate experiments. (3)Validation of the capture performance of the NPA antibody for MERS-CoV, HKU1-CoV and OC43-CoV N antigens by competitive ELISAThe competitive ELISA was established to evaluate the capture capability of the NPA antibody against the N proteins of MERS-CoV, HKU1-CoV and OC43-CoV. The NPA antibody was coated onto ELISA plates as the capture antibody followed by incubation with MERS-CoV, HKU1-CoV or OC43-CoV N antigens separately. Then, SARS-CoV-1 N protein was added followed by incubation with the HRP-conjugated anti-SARS-CoV-1 N protein antibody as the detection antibody. As shown in Fig. 8, the OD values of the experimental groups that included competitive MERS-CoV, HKU1-CoV or OC43-CoV N antigens were all reduced compared with the control group (without competing antigen). Statistical analysis using the t-test revealed p-values <0.05, indicating a significant difference compared to blank control. The results demonstrated that the three N proteins effectively competed with SARS-CoV-1 N protein for binding to the NPA antibody, thereby confirming that the NPA antibody could capture the N proteins of MERS-CoV, HKU1-CoV and OC43-CoV.Fig. 8Validation of the capture performance of the NPA antibody for MERS-CoV, HKU1-CoV and OC43-CoV N antigens by competitive ELISA. (The blank control represents wells without competitive N proteins of MERS-CoV, HKU1-CoV and OC43-CoV, processed identically. *** p < 0.05 represents significant difference compared to blank control. Data for each group represented the mean of three independent replicate experiments.).Fig 8 dummy alt text Validation of the capture performance of the NPA antibody for MERS-CoV, HKU1-CoV and OC43-CoV N antigens by competitive ELISA The competitive ELISA was established to evaluate the capture capability of the NPA antibody against the N proteins of MERS-CoV, HKU1-CoV and OC43-CoV. The NPA antibody was coated onto ELISA plates as the capture antibody followed by incubation with MERS-CoV, HKU1-CoV or OC43-CoV N antigens separately. Then, SARS-CoV-1 N protein was added followed by incubation with the HRP-conjugated anti-SARS-CoV-1 N protein antibody as the detection antibody. As shown in Fig. 8, the OD values of the experimental groups that included competitive MERS-CoV, HKU1-CoV or OC43-CoV N antigens were all reduced compared with the control group (without competing antigen). Statistical analysis using the t-test revealed p-values <0.05, indicating a significant difference compared to blank control. The results demonstrated that the three N proteins effectively competed with SARS-CoV-1 N protein for binding to the NPA antibody, thereby confirming that the NPA antibody could capture the N proteins of MERS-CoV, HKU1-CoV and OC43-CoV.Fig. 8Validation of the capture performance of the NPA antibody for MERS-CoV, HKU1-CoV and OC43-CoV N antigens by competitive ELISA. (The blank control represents wells without competitive N proteins of MERS-CoV, HKU1-CoV and OC43-CoV, processed identically. *** p < 0.05 represents significant difference compared to blank control. Data for each group represented the mean of three independent replicate experiments.).Fig 8 dummy alt text Validation of the capture performance of the NPA antibody for MERS-CoV, HKU1-CoV and OC43-CoV N antigens by competitive ELISA. (The blank control represents wells without competitive N proteins of MERS-CoV, HKU1-CoV and OC43-CoV, processed identically. *** p < 0.05 represents significant difference compared to blank control. Data for each group represented the mean of three independent replicate experiments.). (4)The reactivity of NPA antibodies in detecting real clinical samplesThroat swab specimens collected from SARS-CoV-2 infected patients were selected to represent a real-world clinical application setting. Following the same protocol, the sandwich ELISA was conducted to validate the capture performance of the NPA antibody for the N protein in authentic clinical specimens. As shown in Table 3, the cut-off value was determined to be 0.0308, which was calculated as the mean value of OD450 nm derived from negative sample wells plus three times their standard deviation, and 6 of 8 nucleic acid-positive specimens yielded positive detection results. The results collectively demonstrated that the NPA antibody prepared in the study could be used as the capture antibody in β-coronavirus antigen detection.Table 3Reaction of NPA antibody against clinical specimens as the capture antibody by sandwich ELISA.Table 3 dummy alt textclinical specimenss1s2s3s4s5s6s7s8Nucleic acid TestPositive(Ct=37.5)Positive(Ct=32.0)Positive(Ct=19.1)Positive(Ct=22.0)Positive(Ct=15.8)Positive(Ct=19.7)negativenegativeODValue0.01970.02890.15280.17180.26760.19130.01770.0179ReactionImageImage, table 3 dummy alt textclinical specimensS9S10S11S12S13S14BlankControlPositiveControlNucleic acid TestnegativenegativenegativePositive(Ct=23.0)Positive(Ct=27.0)negative————ODValue0.01900.02060.02710.13150.12910.01880.01120.9654ReactionImageImage, table 3 dummy alt textNote: The OD values corresponded one-to-one with the wells in the color reaction image with different clinical specimens (s1∼s8). The clinical specimens were detected using SARS-CoV-2 Nucleic Acid Detection Kit (Fluorescence RT-PCR) from BioPerfectus Technologies Co., Ltd. The blank control and positive control were prepared by replacing clinical specimens with 1% BSA and 5 μg/mL N protein of SARS-CoV-2, respectively. The reactivity of NPA antibodies in detecting real clinical samples Throat swab specimens collected from SARS-CoV-2 infected patients were selected to represent a real-world clinical application setting. Following the same protocol, the sandwich ELISA was conducted to validate the capture performance of the NPA antibody for the N protein in authentic clinical specimens. As shown in Table 3, the cut-off value was determined to be 0.0308, which was calculated as the mean value of OD450 nm derived from negative sample wells plus three times their standard deviation, and 6 of 8 nucleic acid-positive specimens yielded positive detection results. The results collectively demonstrated that the NPA antibody prepared in the study could be used as the capture antibody in β-coronavirus antigen detection.Table 3Reaction of NPA antibody against clinical specimens as the capture antibody by sandwich ELISA.Table 3 dummy alt textclinical specimenss1s2s3s4s5s6s7s8Nucleic acid TestPositive(Ct=37.5)Positive(Ct=32.0)Positive(Ct=19.1)Positive(Ct=22.0)Positive(Ct=15.8)Positive(Ct=19.7)negativenegativeODValue0.01970.02890.15280.17180.26760.19130.01770.0179ReactionImageImage, table 3 dummy alt textclinical specimensS9S10S11S12S13S14BlankControlPositiveControlNucleic acid TestnegativenegativenegativePositive(Ct=23.0)Positive(Ct=27.0)negative————ODValue0.01900.02060.02710.13150.12910.01880.01120.9654ReactionImageImage, table 3 dummy alt textNote: The OD values corresponded one-to-one with the wells in the color reaction image with different clinical specimens (s1∼s8). The clinical specimens were detected using SARS-CoV-2 Nucleic Acid Detection Kit (Fluorescence RT-PCR) from BioPerfectus Technologies Co., Ltd. The blank control and positive control were prepared by replacing clinical specimens with 1% BSA and 5 μg/mL N protein of SARS-CoV-2, respectively. Table 3Reaction of NPA antibody against clinical specimens as the capture antibody by sandwich ELISA.Table 3 dummy alt textclinical specimenss1s2s3s4s5s6s7s8Nucleic acid TestPositive(Ct=37.5)Positive(Ct=32.0)Positive(Ct=19.1)Positive(Ct=22.0)Positive(Ct=15.8)Positive(Ct=19.7)negativenegativeODValue0.01970.02890.15280.17180.26760.19130.01770.0179ReactionImageImage, table 3 dummy alt textclinical specimensS9S10S11S12S13S14BlankControlPositiveControlNucleic acid TestnegativenegativenegativePositive(Ct=23.0)Positive(Ct=27.0)negative————ODValue0.01900.02060.02710.13150.12910.01880.01120.9654ReactionImageImage, table 3 dummy alt textNote: The OD values corresponded one-to-one with the wells in the color reaction image with different clinical specimens (s1∼s8). The clinical specimens were detected using SARS-CoV-2 Nucleic Acid Detection Kit (Fluorescence RT-PCR) from BioPerfectus Technologies Co., Ltd. The blank control and positive control were prepared by replacing clinical specimens with 1% BSA and 5 μg/mL N protein of SARS-CoV-2, respectively. Reaction of NPA antibody against clinical specimens as the capture antibody by sandwich ELISA. Note: The OD values corresponded one-to-one with the wells in the color reaction image with different clinical specimens (s1∼s8). The clinical specimens were detected using SARS-CoV-2 Nucleic Acid Detection Kit (Fluorescence RT-PCR) from BioPerfectus Technologies Co., Ltd. The blank control and positive control were prepared by replacing clinical specimens with 1% BSA and 5 μg/mL N protein of SARS-CoV-2, respectively. Discussion β-HCoVs are a group of viruses that invade the respiratory tract and cause pathological changes in tissues and organs. Viral antigen detection is used as an important auxiliary method for diagnosing viral infection. The viral nucleocapsid (N) protein is more readily detectable and commonly used as the target antigen in viral antigen detection assays due to its high abundance. Typically, coronavirus antigen detection reagents employ the double-antibody sandwich antigen methods, which require the selected antibodies to have high specificity and no cross-reactivity with other subtypes of the same genus. Alternatively, the research approach of this study was to develop antibodies targeting the homologous sequences of viral proteins within the same genus, which were used as capture antibodies for viral antigen detection. The broadly cross-reactive antibodies could universally recognize and capture the five viruses of the same genus, and then combine with another highly specific antibody in the sandwich format to achieve specific detection of the target viral antigen. In the study, the amino acid sequences of the N proteins of five β-HCoVs were aligned, and the homologous peptide segment was selected as the hapten for preparing the broadly cross-reactive antibody. Sequence alignment using the Clustal Omega tool revealed that the peptide fragment (NP) located near the NH₂-terminus of the five N proteins exhibited high sequence homology. We analyzed the spatial distribution of NP within the N protein structure using PyMOL software. The selected peptide is positioned near the N-terminus and exposed on the protein surface, thereby minimizing potential steric hindrance in subsequent antigen–antibody interactions. The B cell linear epitope of NP segments was predicted using the BepiPred3.0 tool, indicating that it was a potential antigenic epitope. The peptide with the length of 12 amino acids had favorable surface accessibility, rational structural localization and reliable predicted antigenicity. It provided a continuous linear antigenic epitope to stimulate the antibodies, which might have a bias in recognizing the spatial epitope of the full-length N protein. A cysteine residue was added at the C-terminus of the NP peptide to provide free sulfhydryl (–SH) group for conjugation with the carrier protein BSA. The peptide-BSA conjugate was used as the immunogen to immunize New Zealand white rabbits. After three booster immunizations, antiserum with a favorable titer was obtained. The antiserum was first purified by ammonium sulfate precipitation method to remove most impurity proteins such as albumin. The further purification was performed by the antigen affinity chromatography which was prepared by coupling the synthetic NP peptides to the resins via -SH groups. The polyclonal antibodies (NPA) with the epitope specificity against NP peptides were obtained with a purity of above 90%. NPA polyclonal antibody has an inherent disadvantage of batch-to-batch variability, while it has the advantage of antigenic epitope diversity, being able to bind to a segment of amino acid sequence rather than just recognizing a single antigenic epitope. That might be beneficial for the broadly cross-reactivity against different β-HCoVs N proteins. In addition, the use of antigen affinity purification columns ensured the stability of antibody specificity. The indirect ELISA was performed to verify the reactivity of the NPA antibody with the N antigens of five β-HCoVs, while the N protein of respiratory syncytial virus (RSV) was used as the negative control. The results showed that the NPA antibody had varying degrees of reactivity with the N antigens of the five β-HCoVs, while no significant reaction was observed with the RSV N protein. The NPA antibody exhibited distinct binding intensities toward N proteins of different β-HCoV subtypes. This discrepancy may result from inconsistencies between the nominal concentrations of commercial N antigens and their actual effective concentrations. Besides, the differences in protein conformational folding among the different viruses might lead to varying accessibility or binding affinity of the NPA antibody to the epitope. Especially, the epitope recognized by the NPA antibody was a continuous linear antigenic sequence. Nonetheless, the results demonstrated that the NPA antibody could recognize the N proteins of five β-HCoVs. Considering the availability of commercial antibodies for the detection antibody, the capture performance of the prepared NPA polyclonal antibody against the N proteins of SARS-CoV-2 and SARS-CoV-1 was evaluated by sandwich ELISA, while the N proteins of MERS-CoV, HKU1-CoV and OC43-CoV were evaluated using the competitive ELISA. The results showed that the NPA antibody could capture N proteins of five β-HCoVs. Nevertheless, the limit of detection (LOD) for SARS-CoV-2 N protein achieved by the NPA-based sandwich ELISA was 62.5 ng/mL, which was higher than the previously reported LOD of 0.74 ng/mL in reference (Liew et al., 2025). The reason might be that NPA antibodies prepared by peptide segment have insufficient antibody affinity and poor conformational epitope matching. Generating high-affinity antibodies with precise matching to native conformational epitopes using short peptide haptens remains a major challenge, which requires further optimization in future studies. Given the limited availability of clinical samples from individuals infected with SARS-CoV-1, MERS-CoV, OC43 and HKU1, throat swab specimens from SARS-CoV-2-infected patients were used to investigate the capture performance against N proteins in real-world clinical samples. 6 of 8 nucleic acid-positive specimens with cycle threshold (Ct) values < 30 yielded positive detection results. The results demonstrated that the NPA antibody was able to capture N proteins in the specimens. The weak chromogenic signal intensity observed in ELISA might be attributed to two primary factors. The clinical throat swab specimens adopted in this study were residual discarded samples originally used for SARS-CoV-2 nucleic acid detection. The preservation buffer in commercial sampling tubes disrupts viral structural integrity and inactivates virions to facilitate nucleic acid release, which may induce conformational changes and partial denaturation of viral N proteins. Such structural alterations significantly reduce the immunoreactivity of N proteins, thereby weakening the signal response in double-antibody sandwich detection. In addition, appropriate paired antibodies should be carefully screened from numerous candidates for establishing a reliable double-antibody sandwich antigen detection system. In the study, self-prepared NPA antibody was used as the capture antibody, while commercially available HRP-conjugated antibody served as the detection antibody. The compatibility and matching efficiency between these two antibodies still require further systematic validation. Collectively, the results demonstrated that the prepared NPA antibody could be used as the capture antibody in antigen detection assays. Further in-depth investigations will be performed focusing on the selection of authentic clinical specimens and optimal pairing strategies for HRP-labeled detection antibodies in subsequent study. Furthermore, alignment of the amino acid sequences of the N proteins from five human β-coronaviruses revealed that the homologous NP peptide was highly conserved, suggesting that the NP peptide was a high specific and conserved sequence among human β-coronavirus N proteins. Therefore, the broadly cross-reactive antibody prepared in the study could not only be used to capture N proteins of currently known human β-coronaviruses but also hold great potential for recognizing N proteins from newly discovered β-HCoVs in the future, which provides significant value for future epidemic preparedness. Conclusion The homologous peptide segments were selected by aligning the amino acid sequences of the N proteins from five β-HCoVs. The synthesized peptides were >95% pure as determined by high-performance liquid chromatography (HPLC), and the actual molecular weights were confirmed to be consistent with the theoretical values by mass spectrometry (MS). The peptides conjugated to BSA were used as immunogens to immunize New Zealand white rabbits. The immune titer of rabbit antisera was determined to be 1:8000 by indirect ELISA. The antisera were purified by ammonium sulfate precipitation combined with antigen affinity chromatography, yielding purified polyclonal antibodies (NPA) with a purity exceeding 95%. It has been verified that the NPA antibody could capture the N proteins of the five β-HCoV subtypes via sandwich ELISA and competitive ELISA. In addition, the self-prepared antibodies were able to capture the N proteins in the throat swab specimens from SARS-CoV-2-infected patients. In summary, the broadly cross-reactive antibody developed in this work could serve as a capture antibody in β-HCoV antigen detection reagents, which holds significant value for future epidemic preparedness. Funding This research was funded by Shandong Provincial Natural Science Foundation of China (ZR2022MH055). Authorship confirmation We confirm that this revised manuscript is original research work of all authors. This manuscript has not been published previously, and is not under consideration for publication in any other journal. All listed authors have fully read, reviewed and approved this revised version of the manuscript. The author order shown in the manuscript has been agreed by all authors, and there are no additional individuals fulfilling authorship criteria omitted from the author list. Ethics statement The study was conducted in accordance with the Declaration of Helsinki, and the protocol of using throat swab clinical specimens was approved by the Ethics Committee of Weifang People's Hospital Medical Research (KYLL20260527-1) on May 27, 2026. The protocol of rabbit immunization was approved by Experimental Animal Ethics Committee of Shandong Second Medical University (2021SDL441) on Nov. 25, 2021. CRediT authorship contribution statement Qiang Wu: Writing – review & editing, Methodology, Funding acquisition, Conceptualization. Zhan-Zhao Wang: Visualization, Investigation, Formal analysis, Data curation. Zhen-Ming Wang: Validation, Resources, Formal analysis. Yu-Hui Wang: Supervision, Resources, Project administration. Declaration of competing interest None.